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The use of expert surrogates to evaluate clinical trials in
non-small cell lung cancer
W.J. Mackillop, G.K. Ward & B. O'Sullivan
McGill Cancer Centre, McGill University, Montreal, Quebec, Canada
One hundred and eighteen doctors who treat pulmonary neoplasms in Ontario were asked how they would
wish to be treated if they had non-small cell lung cancer. Four different scenarios were given. The physicians
were then asked if they would consent to take part as subjects in one or more clinical trials for which they
would be eligible in those situations. The proportion of respondents who would consent to each study ranged
from 11% to 64%. Reasons given for refusing to participate as subjects in each trial were varied, but many
felt that the trials offered unacceptable options for treatment. Medical oncologists consented to each study
more frequently than radiation oncologists, respirologists or thoracic surgeons but all disciplines ranked the 6
studies in the same order of acceptability. It is concluded that some patients with non-oat cell lung cancer
currently receive experimental therapies with high risk/benefits ratios which experts in the field would not
accept for themselves. It is suggested that the expert surrogate system may be useful as an adjunct to the
institutional review board in evaluating new trials before they are activated.
The Nuremberg code (1949) states that the
voluntary consent of the subject is absolutely
essential in human experimentation and the
Declaration of Helsinki in addition demands that
'the potential subject must be adequately informed
of the aims, anticipated benefits and potential
hazards of the study and the discomfort it may
entail' (World Medical Association, 1964). Hence
'informed consent' has become widely accepted as
essential in clinical trials but it has proved difficult
to define and, once defined, difficult to achieve in
practice. Numerous empirical studies have shown
that many patients who have given their 'informed
consent' have little idea of what they have
consented to (Epstein et al., 1969; Robinson et al.,
1976; Schultz et al., 1976; Muss et al., 1979), and
that trust in the doctor and fear of the illness
remain primary reasons for participating in clinical
trials (Penman et al., 1984; Saurbrey et al., 1984).
Fost (1975) suggested that one of the major barriers
to communication is the emotional state of the
patient which, in the context of a serious illness,
may preclude rational consideration of any
proposed study. He has therefore argued for the use
of lay surrogates to evaluate clinical trials. The
essence of this process is to obtain a response from
individuals who are not candidates for
investigations or therapeutic procedures but who
are asked to behave as if they were (Fost, 1975).
The surrogate can reflect on the question with a
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clearer mind than the patient and his decision will
not be influenced by his dependence on the doctor.
The emotional state of the patient is not the only
limitation to the validity of informed consent.
Ingelfinger (1972) said that the trouble with
informed consent is that it is not educated consent,
and Jonas (1969) argued that ultimately the
researcher himself makes the ideal research subject
since it is he who best understands the issues at
stake and the risks involved. We have therefore
tested the use of specialist physicians as surrogates
in the evaluation of clinical trials. This strategy
offers the advantages of Fost's method and, at least
in spirit, meets Ingelfinger's demand that consent
ought to be educated as well as informed. We
chose lung cancer as the index disease because it is
the most common lethal malignancy in the
developed world and is currently the subject of 152
clinical trials registered with the International
Research Data Bank (National Institute of Health,
1983).
Materials and methods
Cancer care in Ontario is centralized through the
Princess Margaret Hospital (PMH) in Toronto, and
the Ontario Cancer Research and Treatment
Foundation (OCTRF) which operates 7 cancer
clinics associated with major general hospitals
throughout the province. With the cooperation of
the chiefs of staff of the PMH and the OCTRF
clinic directors we assembled a list of the 118
specialists who treat lung cancer in these clinics.
Each individual was sent a written questionnaire
which had 4 components: (a) the physicians were
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asked for demographic information and details
of their education and current practice; (b) the
subjects were asked how they personally would
wish to be managed if they had lung cancer (four
specific scenarios were given with open ended
questions); (c) the subjects were then asked if they
would consent to be treated on 6 randomized trials
for which they would be eligible in those situations.
The investigators' summary of each study as
supplied to the International Cancer Research Data
Bank accompanied the questionnaire as an
appendix but was also summarized in the main
body of the form (these questions required yes/no
answers); (d) if the subject would not consent he or
she was asked to identify the arms of the study
which were unacceptable and to explain why.*
Seventy-nine completed questionnaires were
returned. Results were analyzed using the SSPS-X
program (SSPS Inc.): p values given in comparison
of proportions were determined by the x2 test.
Fifty-one of the respondents were Canadian or
US medical graduates and 28 were graduates from
schools outside North America (including 25 from
the United Kingdom or Commonwealth countries).
Thirty-seven practised as radiation oncologists, 28
as medical oncologists, 8 as thoracic surgeons, 4 as
respiratory specialists and 2 were non-specialists
practising in a cancer clinic. All were affiliated with
a university, 74% were fulltime hospital staff and
only 3.8% spent more than half of their time in
private office based practice. Ninety-one percent of
the respondents spent at least 80% of their time
treating cancer patients. Twenty-five respondents
treated between 1 and 10 new lung cancer
patients/year, 30 saw between 11 and 50 new cases,
and 24 saw more than 50 new cases/year. Sixty-
eight percent spent at least 10% of their time on
research, 88% participated actively in clinical trials,
and 77% participated in clinical trials in lung
cancer. Twenty-three of the 79 were, or had been,
habitual smokers.
Results
Situation A
The scenario was as follows:
'You are found on routine chest X-ray to have a
right upper lobe mass with right hilar lymphadeno-
pathy. Bronchoscopy with biopsy show a poorly
differentiated adenocarcinoma arising in the right
upper lobe bronchus without obstruction.
Mediastinoscopy and biopsy shows involvement of
mediastinal nodes with the same tumor. A full
*Copies of the original questionnaire are available on
request.
metastatic work-up is entirely negative. You have
no symptoms attributable to the disease other than
a little fatigue.
Outline how you would wish to be treated.'
Immediate radiation therapy was chosen by 61%,
but 22% wished no immediate treatment. Chemo-
therapy alone or in combination with some other
treatment was chosen by only 5.4%.
Respondents were then asked if they would
consent to participate in Studies I and II for which
they would be eligible in this situation.
Study I was the trial of immediate vs. delayed
radiotherapy in patients with inoperable, non-
symptomatic, non-small cell lung cancer organized
by the Cancer Cooperative Group of the European
Organization for Research on the Treatment of
Cancer (EORTC-08824). It was summarized as
follows in the questionnaire:
RANDOMIZATION
Arm I Arm 2
Radiotherapy. Irradiation Irradiation as in Arm 1
of the primary tumour but only when symptoms
and mediastinal nodes. develop.
Immediate treatment.
Seventy-eight subjects answered the question and
52.6% said that they would consent. Table I shows
that more medical oncologists than radiation
oncologists consented to this study and doctors
who spent more than 10% of their time on research
consented more frequently than those who spent
less time on research. Table II shows the
respondents' reasons for rejecting each arm (more
than one answer was given by some respondents).
Most of the subjects who consented to Study I had,
in the preceding open ended management question,
chosen a treatment which corresponded to one or
other arm of the trial but 40% of those who had
chosen immediate radiation were willing to accept
randomization and 68.8% of those who had
initially chosen no treatment were also willing to
consent.
Study II was a randomized trial of 2 different
chemotherapy regimes from the North Central
Cancer Treatment Group (NCCTG-812451). It was
summarized as follows:
RANDOMIZATION
Arm I Arm 2
4 Drug chemotherapy: 3 Drug chemotherapy:
Methotrexate, 5 FU, Adriamycin and
Adriamycin, CCNU, Mitomycin, alter-
and Cyclophosphamide nating with 2 drug
chemotherapy, 5 FU
and AdriamycinEXPERT SURROGATES AND CLINICAL TRIALS 663
Table I Percentage of doctors who would consent to treatment on protocol.
Postgraduate New cases of Time spent
Smoker training lung CA/year on research
Rad Med
Total Yes No onc onc Other < 10 11-50 >50 >10% <10%
Study I 53 59 50 39b 71" 50 64 45 50 68a 41a
Study II 11 13 11 8 11 17 8 10 17 17 7
Study III 64 70 61 49b 86b 50 80a 67 42a 83c 48c
Study IV 27 4b 36" 21 28 25 17 27 38 32 23
Study V 31 27 32 22 43 42 29 27 38 43a 21a
Study VI 19 9 23 11 25 17 20 20 17 23 16
ap<0.05; bp<0.01 and cP<0.001.
Table II Reasons given for refusing to participate in
study I
A: Reasons Arm I ofStudy I is unacceptable
(7/10 eligible answered)
Wants chemotherapy 2
Radiotherapy is toxic 1
Radiotherapy is not curative 2
Waiting is as good 1
Other 1
B: Reasons Arms II ofStudy I is unacceptable
(30/32 eligible answered)
Delay may mean lost chance of cure 14
Radiotherapy will increase symptom free time 9
Psychologically difficult to wait 6
Wants chemotherapy 2
Other 4
All 79 answered this question of whom only 9
(11.4%) said that they would consent. This study
was uniformly rejected by all groups regardless of
background and experience (Table I). Sixty-four of
the 70 who refused to participate rejected both Arm
1 and Arm 2. The same reasons were given for
rejecting each arm: toxicity of chemotherapy was
mentioned by 75%, ineffectiveness of chemotherapy
was mentioned by 57.8% and 6% indicated that
they wished to have radiotherapy instead.
Situation B
The scenario was as follows:
'You are found on routine chest X-ray to have a
2cm diameter solitary nodule in the (R) upper lobe
4cm from the hilum. Trans thoracic needle aspirate
shows a large cell anaplastic carcinoma. Medias-
tinoscopy with biopsy is negative. A complete
metastatic work-up is negative. You are
asymptomatic.
How would you wish to be treated?'
Eight-one percent wished surgery alone and 12%
wished surgery with or without postoperative
radiation depending on operative findings. Three
percent wanted adjuvant chemotherapy.
Studies III and IV were set in the context of
Situation B.
Study III was a randomized comparison of
lobectomy vs. limited pulmonary resection for T1,
No, non-small cell lung cancer from the Lung
Cancer Study Group (LCSG-821). It was
summarized as follows:
RANDOMIZATION
Arm I Arm 2
Surgery: Lobectomy Surgery: Limited resection
(segmental or wedge)
Seventy-eight of 79 respondents answered this
question of whom 50 (64.1%) said that they would
consent. Medical oncologists consented more
frequently than radiation oncologists and there was
also a significant inverse correlation between
acceptability of the study and the number of new
cases of lung cancer which the respondent treated
each year (Table I). Twenty-six subjects rejected
Arm 2 only and all of these expressed concern that
lesser surgery might be inadequate. Two subjects
rejected both Arm 1 and Arm 2 because they
wished adjuvant treatment.
Study IV was a randomized study of intra-
tumoral BCG prior to surgery for non-small cell
carcinoma of the lung from Yale University
(YALE-LUN-1). It was summarized as follows:
RANDOMIZATION
Arm I Arm 2
Intratumoral BCG Immediate surgery.
followed by lobectomy Lobectomy alone.
2-4 weeks later.
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question of whom 21 (26.9%) said that they would
consent (Table I). Postgraduate training had no
influence on response to this study. Smokers
consented significantly less frequently than non-
smokers and women consented more frequently
than men. Only 3 respondents rejected Arm 2, but
55 rejected Arm 1, of whom 46 (84%) mentioned
that BCG was of no value, 12 (22%) were
concerned about delay in surgery, 9 (16%) men-
tioned BCG toxicity, 4 (7%) specifically mentioned
risk from the BCG injection, and 2 mentioned the
absence of post operative radiotherapy.
Situation C
The scenario was as follows:
'You are found on routine chest X-ray to have a
3cm diameter mass in (R) upper lobe. Broncho-
scopy shows an ulcerative lesion of (R) upper lobe
bronchus. Biopsy shows poorly differentiated
adenocarcinoma. Mediastinoscopy is negative. A
metastatic work-up is negative. A (R) pneumonec-
tomy is carried out. The pathologist reports
extensive nodal involvement including the most
proximal node in the pneumonectomy specimen.
How would you now wish to be treated?'
Sixty-six percent of respondents wished radio-
therapy and 23% wished no immediate treatment.
Study V, which was set in the context of
Situation C above, is a comparison of Chemo-
therapy vs. Radiotherapy vs. Radiotherapy and
Chemotherapy in incompletely resected non-small
cell lung cancer from the Lung Cancer Study
Group (LCSG-791). Arm 1 was closed to entry in
1980, therefore this study as presented below was
not current at the time the survey was carried out.
RANDOMIZATION
ArmI Arm2
Combination Split course, radio-
chemotherapy with therapy (2000rads/
Cyclophosphamide, 5Tx/I week x 2)
Adriamycin and
Cisplatinum
Arm'3
Combination chemo-
therapy (as in 1)
and radiotherapy
(as in 2)
Seventy-eight of 79 subjects answered this question
of whom 24 (30.8%) said that they would consent
(Table I). Of 54 who refused to participate in the
study, 47 rejected Arm 1, 17 rejected Arm 2 and 43
rejected Arm 3. Reasons for rejecting Arms I and 3
were similar: 67-76% mentioned the toxicity of
chemotherapy, 70-74% thought that chemotherapy
was ineffective and 14-15% wanted radiotherapy.
Seven of those who rejected Arm 2 said that
radiotherapy was useless, and 8 said that the
radiation therapy regime was suboptimal.
Situation D
The scenario was as follows:
'You present with 20 pounds weight loss and low
back pain. Chest X-ray shows (L) hilar and
mediastinal adenopathy. Bronchoscopy and biopsy
shows a squamous cell carcinoma of the (L) upper
lobe bronchus. Bone scan shows numerous areas of
increased uptake and a skeletal survey confirms
widespread metastatic disease including the body of
L4.
How would you wish to be managed?
Sixty-nine percent wished radiotherapy to the
painful area with or without other treatment, 20%
wanted symptomatic management only, and 16%
wished chemotherapy either alone or in
combination with radiation.
Study VI, which is set in the context of Situation
D, is a randomized trial of 5 different chemo-
therapy regimes from the South West Oncology
Group (SWOG-8241). The study was summarized
as follows:
RANDOMIZATION
Arm v
Cisplatinum
Adriamycin
Cyclophos-
phamide,
alternating
with 5 FU
Vincristine
Mitomycin
Seventy-nine out of 79 respondents answered this
question of whom 15 (19%) said that they would
consent. Of 64 who refused their consent 58 found
all arms unacceptable. Reasons given for rejecting
all arms of the study include the toxicity of chemo-
therapy (60%), the ineffectiveness of chemotherapyEXPERT SURROGATES AND CLINICAL TRIALS 665
(70%), and the lack of radiotherapy (17%). The
study was uniformly unpopular regardless of the
background and experience of the subjects (Table
I).
Factors affecting consent
We have attempted to look for factors influencing
general attitudes to clinical trials by scoring the
total number of trials to which each respondent
would consent and these data are shown in Figure
1. Neither age nor sex had any influence on
attitudes (Figure 1, panel B, C, D and E). Panels N
and 0 of Figure 1 show that 65% of radiation
oncologists refused all, or all but one of the 6
studies compared to only 14.2% of medical
oncologists (P<0.001). Those who did not actually
treat lung cancer on clinical trials did not differ
from those who did (Figure 1, panels I and J), but
there was a significant correlation between time
spent on research and likelihood of giving consent
(Figure 1, panels K, L and M). The effect of the
number of new cases of lung cancer seen by the
respondent each year was curious (Figure 1, panels
F, G and H). Fifty-four percent of those who
treated more than 50 new lung cancer patients each
year rejected all or all but one of the 6 studies,
compared to 35% of those who treated fewer new
cases (P<0.01) but 16.7% of this same high case
load group were at the opposite extreme and
consenting to all or all but one of the studies,
compared to only 1.8% of those who saw fewer
cases of lung cancer (P<0.05). Smokers showed no
overall difference in attitude to the 6 trials
compared to non-smokers. Our reason for studying
the influence of smoking history was that for
smokers these questions, though hypothetical, were
very real ones which we believed they might have
asked themselves previously. In their evaluation of
these clinical trials the smokers do appear to be
more discriminating than the rest, in that those
studies which were popular overall were even more
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acceptable to the smokers and those which were
generally unpopular were even less acceptable to
the smokers (see Table I).
Discussion
Four open ended management questions posed to
expert surrogates elicited answers which were
surprisingly consistent in view of the diverse
backgrounds of our respondents. In each situation
more than 80% of answers fell into 1 or 2
categories only. There was always a single preferred
treatment chosen by 60% or more but, despite this
consensus, there was evidence of an important
difference of opinion in 3 of the 4 situations where
an alternative treatment was chosen by about 20%.
Only one of the 6 clinical trials studied here
addressed a controversy defined by the subjects in
their answers to the open-ended management
questions. In Situation A the majority chose
immediate radiation therapy while a significant
minority opted for no immediate treatment. Study
I, which addresses this controversy, was acceptable
to more than 50% of the respondents. Most of
those who consented had initially chosen treatment
equivalent to one or other arm of the study but
their willingness to consent to randomization
suggests that they acknowledge that there is
uncertainty as to optimal management in this
situation. Some of those who refused to participate
rejected Arm I of the study while others rejected
Arm 2, and their varied reasons for refusing simply
reiterate the controversy which the study is
designed to address.
The reaction of the subjects to Study II in the
same setting is quite different. Very few surrogates
consented and reasons for refusal were uniform.
This could have been predicted from the
respondents' answers to the management question.
Only 2 of the 74 who answered wished treatment
with chemotherapy alone and their responses thus
give no evidence of any real controversy as to its
value. Thus the expert surrogates may be of value
in defining areas of controversy which ought to be
addressed in clinical trials. Our results suggest that
studies designed on this basis would prove
acceptable to the majority of experts in the field.
The proportion of doctors who would consent to
participate as subjects in the clinical trials ranged
from 11.4% for Study II to 64.1% for Study III.
Only 2 of. the clinical trials evaluated were
acceptable to more than half of our surrogates and
4 were rejected by two thirds or more. The
difference in acceptability between the most popular
(Study III, 64.1% consent) and the least popular
(Study II, 11.4% consent) was statistically highly
significant (P<0.00001). There are also statistically
significant differences between either of the 2
studies accepted by the majority and any of the 4
studies rejected by the majority (P<0.005 in every
case). Surrogate refusal to participate in a trial
might merely indicate the existence of prejudices
which the study was designed to overcome but our
data suggest that this is not the case: if the subjects
irrationally rejected clinical trials because of
unfounded personal preferences, some subjects
should reject one arm while other subjects should
reject the other. In contrast, in any of the 4 trials
which were rejected by the majority, either one arm
was singled out for rejection (as in Study IV) or all
arms were rejected (as in Study II). Furthermore,
while medical oncologists were in any given
situation more likely to consent than radiation
oncologists, we find that both groups of doctors
rank the studies in the same order of acceptability
(see Table I). Likewise, those doctors who do
research were more likely overall to consent than
those who are not active in research (Figure 1) but
both groups were in complete agreement about the
order of acceptability of the 6 trials (see Table I).
Thus the differences between the studies cannot be
explained as merely reflecting bias engendered by
background and training.
Reasons given by surrogates for their refusal to
participate may be important also in assessing the
more frequently accepted studies. In Situation B we
found no evidence of any controversy in the choices
of management of our respondents, but 64.1%
consented to participate in Study III, a comparison
of standard therapy by lobectomy with lesser
surgery. Thus Study III seems even more acceptable
than Study I but an examination of the reasons
given for refusal reveals important differences
between these two studies. Those who rejected
Study I did so for diverse reasons but those who
rejected Study III rejected one particular arm and
did so for a single cogent reason. Furthermore, the
study was least acceptable to those doctors with the
greatest experience in the management of lung
cancer.
The Ontario clinics are non-surgical oncology
centers so that thoracic surgeons were under-
represented on our list of doctors who treat lung
cancer in Ontario. The exhaustive nature of the
sample and the high response rate (67%), however,
provide us with some assurance that the views of
medical and radiation oncologists in the province
have been fairly represented. We have no reason to
doubt that this reflects opinion in the rest of
Canada, but we cannot extrapolate beyond our
own borders. It is, however, interesting that British
trained doctors in this study did not differ in their
views from their North American trained
colleagues. We do not, of course, know if doctors
in other specialities or in general practice would giveEXPERT SURROGATES AND CLINICAL TRIALS 667
the same sort of answers but the very similar views
expressed here by the different disciplines makes it
unlikely that there would be major variations in
opinion across the profession.
The clinical trials which our surrogates evaluated
were chosen by us to exemplify different types of
study which were then in progress in non-small cell
lung cancer. They were not picked randomly and
may not be representative in content or quality of
the ongoing work in the field. Nonetheless, the
finding that most specialists who treat lung cancer
would not consent to participate as subjects in
many of these trials is of concern. If experts refuse
to participate in a trial, should uncomprehending
patients be asked to consent? It is likely that
opinions will vary on this point so we have
resubmitted our results to the original respondents
to obtain their views, and to find out if there is any
consensus as to how to act on this type of
information. If the method proves to have general
credibility, expert surrogates may be a useful
adjunct to institutional review boards or ethics
committees in evaluating the acceptability of new
protocols. The growing pressure on doctors to
carry out clinical trials and publish their results
makes it essential to take every possible step to
protect the patient's interests. It can be argued that
sufficient safeguards already exist but we believe
that there have been insufficient empirical studies of
the clinical trials process to be sure of this
(Mackillop & Johnston, 1985).
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